Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 8/20 | 0.36 |
| ▸ | PYGL | P06737 | 3/20 | 0.36 |
| ▸ | PYGM | P11217 | 2/20 | 0.36 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18537499 | 1.00 | PYGB (0.36) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL21539187 | 1.00 | PYGB (0.36) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL13559216 | 1.00 | PYGB (0.36) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL18681231 | 1.00 | PYGB (0.36) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL12658343 | 1.00 | PYGB (0.36) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL16918679 | 1.00 | PYGB (0.36) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL13010055 | 1.00 | PYGB (0.36) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL12899851 | 0.77 | PYGB (0.38) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL13787598 | 0.77 | PYGB (0.38) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL12929272 | 0.77 | PYGB (0.38) | PYGBPYGLPYGMOGALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160031927-A1 | Alkyl 2--propionates, nucleoside inhibitors of HCV RNA-polymerase NS5B, methods for preparation and use thereof | IVACHTCHENKO ALEXANDRE VASILIEVICH (RU) | 2016-02-04 | — | — | US | disclosed |
| EP-2977379-A1 | ALKYL 2-{[(2R,3S,5R)-5-(4-AMINO-2-OXO-2 -PYRIMIDIN-1-YL)-3-HYDROXY- TETRAHYDRO-FURAN-2-YL-METHOXY]-PHENOXY-PHOSPHORYL-AMINO}-PROPIONATES, NUCLEOSIDE INHIBITORS OF HCV NS5B RNA-POLYMERASE, AND METHODS FOR PRODUCING AND USE THEREOF | Ivachtchenko, Alexandre Vasilievich (RU) | 2016-01-27 | — | — | EP | disclosed |
| WO-2014148949-A1 | ALKYL 2-{[(2R,3S,5R)-5-(4-AMINO-2-OXO-2Н-PYRIMIDIN-1-YL)-3-HYDROXY- TETRAHYDRO-FURAN-2-YL-METHOXY]-PHENOXY-PHOSPHORYL-AMINO}-PROPIONATES, NUCLEOSIDE INHIBITORS OF HCV NS5B RNA-POLYMERASE, AND METHODS FOR PRODUCING AND USE THEREOF | АСАВИ, ЛЛС (US) | 2014-09-25 | — | — | WO | disclosed |
| US-8158779-B2 | Antiviral nucleosides | MEDIVIR AB (SE) | 2012-04-17 | — | — | US | disclosed |
| US-8158779-B2 | Antiviral nucleosides | MEDIVIR AB (SE) | 2012-04-17 | — | — | US | disclosed |
| US-20110281747-A1 | BIOMARKERS FOR PREDICTING RAPID RESPONSE TO HCV TREATMENT | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110172410-A1 | ANTIVIRAL NUCLEOSIDES | MEDIVIR AB (SE) | 2011-07-14 | — | — | US | disclosed |
| US-20110172410-A1 | ANTIVIRAL NUCLEOSIDES | MEDIVIR AB (SE) | 2011-07-14 | — | — | US | disclosed |
| US-7935681-B2 | Antiviral nucleosides | MEDIVIR AB (SE) | 2011-05-03 | — | — | US | disclosed |
| US-20110015148-A1 | ANTIVIRAL NUCLEOSIDES | MEDIVIR AB (SE) | 2011-01-20 | — | — | US | disclosed |
| US-20100130735-A1 | ANTIVIRAL NUCLEOSIDES | MEDIVIR AB (SE) | 2010-05-27 | — | — | US | disclosed |
| US-7666856-B2 | such as 4-Amino-1-((2R,3S,4S,5R)-5-azido-4-hydroxy-5-hydroxymethyl-3-methyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one, used for the treatment or prophylaxis of viral diseases; hepatitis C viral infection | MEDIVIR AB (SE) | 2010-02-23 | — | — | US | disclosed |
| US-7645745-B2 | Propionic Acid (2R,3R,4R,5R)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-4-hydroxy-4-methyl-3-propionyloxy-tetrahydro-furan-2-ylmethyl ester; inhibit RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase | ROCHE PALO ALTO LLC (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645745-B2 | Propionic Acid (2R,3R,4R,5R)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-4-hydroxy-4-methyl-3-propionyloxy-tetrahydro-furan-2-ylmethyl ester; inhibit RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase | ROCHE PALO ALTO LLC (US) | 2010-01-12 | — | — | US | disclosed |
| US-20080152621-A1 | Antiviral nucleosides | ROCHE PALO ALTO LLC | 2008-06-26 | — | — | US | disclosed |
| US-7378402-B2 | 4-Amino-1-((2R,3S,4S,5R)-5-azido-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one; hepatitis C virus. | ROCHE PALO ALTO LLC (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378402-B2 | 4-Amino-1-((2R,3S,4S,5R)-5-azido-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one; hepatitis C virus. | ROCHE PALO ALTO LLC (US) | 2008-05-27 | — | — | US | disclosed |
| US-20070232562-A1 | Antiviral nucleosides | ROCHE PALO ALTO LLC | 2007-10-04 | — | — | US | disclosed |
| US-20070232562-A1 | Antiviral nucleosides | ROCHE PALO ALTO LLC | 2007-10-04 | — | — | US | disclosed |
| US-20070197463-A1 | Antiviral nucleosides | PHARMASSET, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172410-A1 | ANTIVIRAL NUCLEOSIDES | PNP, MTAP, UMPS | PYGB 4057/4885PYGL 139/4885PYGM 1735/4885 |
| US-20080152621-A1 | Antiviral nucleosides | PNP, MTAP, UMPS | PYGB 4057/4885PYGL 139/4885PYGM 1735/4885 |
| US-20070232562-A1 | Antiviral nucleosides | RNGTT, PNP, NSUN2 | PYGB 4523/4885PYGL 364/4885PYGM 3270/4885 |
| US-20070197463-A1 | Antiviral nucleosides | RNGTT, PNP, NSUN2 | PYGB 4245/4885PYGL 230/4885PYGM 2768/4885 |
| US-20110015148-A1 | ANTIVIRAL NUCLEOSIDES | PNP, MTAP, UMPS | PYGB 4057/4885PYGL 139/4885PYGM 1735/4885 |
| US-20100130735-A1 | ANTIVIRAL NUCLEOSIDES | PNP, MTAP, UMPS | PYGB 4057/4885PYGL 139/4885PYGM 1735/4885 |
| US-20160031927-A1 | Alkyl 2--propionates, nucleoside inhibitors of HCV RNA-polymerase NS5B, methods for preparation and use thereof | RNGTT, NSUN2, MED1 | PYGB 4522/4885PYGL 1939/4885PYGM 3314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.